Ramatroban
![]() | |
Clinical data | |
---|---|
Trade names | Baynas |
AHFS/Drugs | International Drug Names |
Routes of administration | Oral (tablets) |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard(EPA) | |
ECHA InfoCard | 100.159.668 |
Chemical and physical data | |
Formula | C21H21FN2O4S |
Molar mass | 416.47g·mol−1 |
3D model (JSmol) | |
| |
|
Ramatroban(INN) (also known asBAY u3405)[1]is athromboxane receptor antagonist.[2]
It is also aDP2receptorantagonist.[3]
It is indicated for the treatment ofcoronary artery disease.[4]It has also been used for the treatment ofasthma.[5]
It has been suggested that ramatroban, by modulatingDP2receptor,can reverse viremia-associated proinflammatory and prothrombotic processes which are similar to those induced bySARS-Cov-2.[citation needed]Hence, ramatroban, that has been used for the treatment of allergic rhinitis in Japan for the past two decades with a well established safety profile, merits investigation as a novel immunotherapy for the treatment ofCOVID-19disease, although no clinical trial has yet been conducted.[6]
Ramatroban was developed by the German pharmaceutical companyBayer AGand is co-marketed inJapanby Bayer Yakuhin then marketed by Kyorin Pharmaceutical and Nippon Shinyaku Co., Ltd. under the trade nameBaynas.
References
[edit]- ^"Ramatroban (compound)".PubChem.National Center for Biotechnology Information.Retrieved22 June2019.
- ^Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro".The Journal of Pharmacology and Experimental Therapeutics.305(1): 347–352.doi:10.1124/jpet.102.046748.PMID12649388.S2CID10016709.
- ^Royer JF, Schratl P, Carrillo JJ, Jupp R, Barker J, Weyman-Jones C, et al. (September 2008)."A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils".European Journal of Clinical Investigation.38(9): 663–671.doi:10.1111/j.1365-2362.2008.01989.x.PMID18837743.
- ^Fiedler VB, Seuter F, Perzborn E (December 1990)."Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease"(PDF).Stroke.21(12 Suppl): IV149–IV151.PMID2260140.
- ^Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]".Nihon Rinsho. Japanese Journal of Clinical Medicine(in Japanese).54(11): 3045–3048.PMID8950952.
- ^Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN (September 2020)."Pharmaco-Immunomodulatory Therapy in COVID-19".Drugs.80(13): 1267–1292.doi:10.1007/s40265-020-01367-z.PMC7372203.PMID32696108.
External links
[edit]- (in Japanese)Baynas Tablets Prescribing Information